Search PubMed⌕ Search

Biomedical subjects

E T Yin

Publications and source records attributed to E T Yin.

27 records · Page 2Linked to original sources
PubMed1970

Reactions of activated factor X-phosphatide mixtures in vitro and in vivo.

The composition, surface properties, and capacity of lipid particles to bind activated factor X can be correlated both with the influence of various phosphatide combinations on activated factor X activity in vitro and on the intensity and duration of the thrombogenic stimulus as measured by a standard bioassay for thrombus formation. The measurable activity of activated factor X in vitro increased as a linear function of lipid concentration from 0 to 40 micro moles/liter. The effectiveness of the lipids examined was in the following decreasing order: phosphatidyl serine-phosphatidylcholine mixture, "cephalin", and phosphatidyl serine alone. An increase in the duration of hypercoagulability with increasing lipid concentration was also observed, but, with regard to the three lipid fractions tested, the in vivo system appeared to be more discriminatory than in vitro assays. Lipid mixtures containing phosphatidyl serine with either phosphatidylcholine, phosphatidyl ethanolamine, or cetyltrimethylammonium bromide markedly enhanced the in vitro activity of activated factor X. Phosphatidic acid-phosphatidylcholine mixtures had a similar but smaller effect, and phosphatidyl ethanolamine-phosphatidylcholine mixtures were inert. The duration of the hypercoagulability was similarly related to the composition of the phosphatide infused. In mixtures containing phosphatidyl serine, the surface charge density of the lipid particles and the binding of the activated factor X activity to lipid showed some correlations with the in vitro activated factor X assay and with the intensity and duration of the thrombogenic stimulus. These data suggest that the catalytic effect of phosphatides on prothrombin activation and their role in the retardation of in vivo compensatory mechanisms directed against circulating activated factor X, are dependent on the affinity of activated factor X for the lipid surface.

Animals↗
PubMed1965

Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus.

A circulating anticoagulant in a suspected case of lupus erythematosus has been highly purified by a combination of Sephadex gel filtration and DEAE cellulose chromatography. The inhibitor is a gamma globulin with a sedimentation coefficient of 6.6 Svedberg units. For its anticoagulant action, the lupus inhibitor requires a co-factor which is present both in the lupus and normal blood. The cofactor is located in the gamma globulins fraction which is relatively heat stable, but less than the inhibitor, at 56 degrees C. The active lupus inhibitor (inhibitor + cofactor) is not species specific against human prothrombin. Working with highly purified systems, the active inhibitor is found to inhibit prothrombin conversion by formed prothrombin activator. It does not appear to inhibit the formation of prothrombin activator nor does it affect purified prothrombin.

Adult↗